Pharmacia & Upjohn's Rescriptor ACTG 261 data could support approval; FDA cmte. split decision.
Executive Summary
PHARMACIA & UPJOHN RESCRIPTOR ACTG 261 DATA COULD SUPPORT ACCELERATED APPROVAL of the non- nucleoside transcriptase inhibitor, FDA's Antiviral Drugs Advisory Committee agreed at its Nov. 22 meeting. The ACTG 261 trial is expected to be completed by mid-December and analyzed by mid-January.